Li Qiang, Premier of the People's Republic of China

When Li Qiang rose to deliver China's keynote at the Annual Meeting of the New Champions in Dalian, he was speaking to a room accustomed to hearing about export volumes and factory capacity. The subject that now sits alongside those themes is older and more intimate: how a country of 1.4 billion people grows old. By the end of 2025 China had 323 million citizens aged 60 and above, some 23 per cent of the population. The government wants average life expectancy near 80 years by 2030. The premier presides over a planning system that treats that ambition as an economic variable, and the 15th Five-Year Plan period is expected to direct policy attention to biotechnology, medical devices and digital health accordingly.

The relevance to Britain begins with that ownership. Whatever one makes of China's political model, someone at the apex of the state answers for whether demography, industrial policy and care delivery connect. Li has become the visible author of that connection. His government can set a life expectancy target, align research funding and reimbursement behind it, and be held to the result.

Britain's position is harder to describe in a sentence. The waiting list stands above seven million. Resident doctors have taken repeated industrial action. NHS England is being folded into the Department of Health and Social Care, a reorganisation that will absorb management attention for years. The ten-year plan promises a move towards prevention, community care and digital services, and the life sciences sector plan promises investment and faster trials. Responsibility for delivering all of this is spread across the Treasury, the health department, the business department, the technology department, the medicines regulator, the appraisal body, integrated care boards and several hundred provider trusts. Each can plausibly claim the strategy belongs to someone else.

Scale is where Chinese and British experience diverge most usefully. Basic medical insurance in China covers around 95 per cent of the population, which gives developers an enormous testing ground for artificial intelligence and digital therapeutics. The country's own policy discussion concedes that volume of data does not amount to quality of evidence. Records must be accurate, interoperable and clinically meaningful before they change a decision at the bedside. Britain has the reverse problem. It holds one of the world's most coherent longitudinal health datasets, a single payer, a national appraisal body and a trial network with real standing. Yet it struggles to convert those assets into speed. Setting up a multi-site trial can take months longer than competitors manage, and public suspicion of data sharing, sharpened by arguments over the federated data platform and the use of patient records in commercial research, constrains what the NHS can do with its own information.

The corporate dimension is where the connection becomes direct. In 2025 companies in Greater China completed 186 cross-border out-licensing deals worth $137.7 billion. Many of these firms were designed from the outset for international validation, running trials with overseas regulators in mind and signing partnerships with multinational pharmaceutical groups before they had a domestic commercial footprint. British consequences follow without much mediation. UK-headquartered pharmaceutical companies are among the buyers of these assets. Medicines first developed in Chinese laboratories will arrive at the medicines regulator and the appraisal body with trial populations that may not resemble British patients. Decisions on regulatory reliance, on the weight given to data generated abroad and on the evidence needed for local adoption will become routine rather than exceptional. UK biotech firms, meanwhile, compete for the same partners and the same capital.

The connection is weaker, and more politically contingent, in service delivery. The NHS is not about to import a Chinese model of hospital operations, and nobody serious proposes it. In digital health and devices the relationship is cautionary. Genetic and clinical data are among the most sensitive categories the state holds, and cross-border transfer rules in both countries are tightening. Procurement of connected equipment and AI tools carries security questions that sit awkwardly with a service desperate for productivity gains. Ministers have shown little consistency on how to treat Chinese investment and supply, oscillating between courtship and suspicion depending on the week. NHS leaders cannot resolve that tension themselves, yet they will be the ones signing contracts while it remains unresolved.

The practical implications follow from this. Trust chief executives and integrated care board leaders should expect due diligence on supplier provenance to become a standard part of digital procurement, and should press the centre for clear rules before they need them. Policymakers should treat the regulatory interface with new global biotech models as an operational matter for the next two years, with the regulator and the appraisal body resourced to assess evidence generated in unfamiliar settings. Health-tech and life sciences businesses should assume that partnerships with Chinese counterparts will attract scrutiny, and should build data governance that would survive a hostile reading. Patients will mostly notice none of this, until a new therapy arrives sooner or later than it otherwise would.

Li Qiang's address does not offer Britain a template. Centralised direction produces its own failures, and a Five-Year Plan cannot be transplanted into a system governed by ministerial turnover, devolved administrations and a sceptical public. What it offers is a clear instance of a head of government attaching his name to the proposition that population health and economic strength are the same project. A British prime minister who wished to make the equivalent claim would need a single accountable line running from the Treasury settlement to the ward, and at present that line does not exist. The reforms now under way will be judged by whether they supply it before 2030.